King International Investment Limited (HKG:0928)
0.0640
+0.0010 (1.59%)
Jul 10, 2026, 4:08 PM HKT
HKG:0928 Revenue
In the fiscal year ending March 31, 2026, King International Investment had annual revenue of 143.23M HKD with 251.35% growth. King International Investment had revenue of 69.31M in the half year ending March 31, 2026, a decrease of -53.87%.
Revenue
143.23M
Revenue Growth
+251.35%
P/S Ratio
0.83
Revenue / Employee
11.02M
Employees
13
Market Cap
118.43M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 143.23M | 102.46M | 251.35% |
| Mar 31, 2025 | 40.77M | -192.92M | -82.56% |
| Mar 31, 2024 | 233.68M | 9.83M | 4.39% |
| Mar 31, 2023 | 223.85M | 130.98M | 141.03% |
| Mar 31, 2022 | 92.87M | -9.17M | -8.98% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 6.61B |
| Adicon Holdings | 2.94B |
| Kindstar Globalgene Technology | 1.04B |
| Yunkang Group | 669.23M |
| Mega Genomics | 275.03M |
| Biosino Bio-Technology and Science Incorporation | 205.08M |
| Zhong Ji Longevity Science Group | 126.10M |
| Guanze Medical Information Industry (Holding) | 98.42M |